JP2020529830A5 - - Google Patents

Info

Publication number

JP2020529830A5

JP2020529830A5 JP2019569676A JP2019569676A JP2020529830A5 JP 2020529830 A5 JP2020529830 A5 JP 2020529830A5 JP 2019569676 A JP2019569676 A JP 2019569676A JP 2019569676 A JP2019569676 A JP 2019569676A JP 2020529830 A5 JP2020529830 A5 JP 2020529830A5

Authority

JP

Japan

Prior art keywords

amino acid

seq

acid sequence

sequence shown

cdr1

Prior art date

2018-06-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 126
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 42
• 239000000427 antigen Substances 0.000 claims 33
• 108091007433 antigens Proteins 0.000 claims 33
• 102000036639 antigens Human genes 0.000 claims 33
• 108091008874 T cell receptors Proteins 0.000 claims 31
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 31
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 22
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 22
• 210000004027 cell Anatomy 0.000 claims 11
• 108020004707 nucleic acids Proteins 0.000 claims 6
• 150000007523 nucleic acids Chemical class 0.000 claims 6
• 102000039446 nucleic acids Human genes 0.000 claims 6
• 210000001744 T-lymphocyte Anatomy 0.000 claims 4
• 125000000539 amino acid group Chemical group 0.000 claims 4
• 239000012634 fragment Substances 0.000 claims 4
• 150000001413 amino acids Chemical class 0.000 claims 3
• 239000012472 biological sample Substances 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 238000000034 method Methods 0.000 claims 3
• 230000002265 prevention Effects 0.000 claims 3
• 108090000623 proteins and genes Proteins 0.000 claims 3
• 238000006467 substitution reaction Methods 0.000 claims 3
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 238000012217 deletion Methods 0.000 claims 2
• 230000037430 deletion Effects 0.000 claims 2
• 238000003745 diagnosis Methods 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 238000003780 insertion Methods 0.000 claims 2
• 230000037431 insertion Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000002062 proliferating effect Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 108091026890 Coding region Proteins 0.000 claims 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000000833 heterodimer Substances 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 210000004698 lymphocyte Anatomy 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 claims 1
• 229940127557 pharmaceutical product Drugs 0.000 claims 1
• 239000002243 precursor Substances 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims 1
• 239000003381 stabilizer Substances 0.000 claims 1